Triton Biosciences, Inc. was a biotechnology research company that focused on cancer diagnosis and treatment products. The company began in 1983 as a wholly owned subsidiary of Shell Oil Company. Triton Biosciences partnered with Cetus Corporation, a leading biotechnology research firm. By 1990, Triton had grown to approximately 300 employees and had two pharmaceutical products in late-stage development: Betaseron and Fludara. Betaseron is an injectable drug that is approved for use and treatment of symptoms of multiple sclerosis. Fludara is a chemotherapy medication approved for use and treatment of leukemia and lymphoma. The Triton Biosciences, Inc. records document the company's structure, goals, operations, research, and achievements from its formation to its sale to Schering AG. The collection is arranged into two series: General files and Evaluations and offerings. The General files series consists of presentations, publications, meeting minutes, and marketing materials. The Evaluations and offerings series consists of consulting groups' company analyses of Triton, Triton's self-assessment, prospective buyers' offering memorandums, and materials related to Triton's sale to Schering AG. This collection would interest those researching biotechnology, the pharmaceutical industry, patent medicine development, or company acquisitions.